Fig 1.
Study flow chart.
Table 1.
Characteristics of studies included in the meta-analysis.
Table 2.
Meta-analysis results.
Fig 2.
RRs and 95% CIs for (A) 2-year relapse risk and (B) 5-year OS, according to a subgroup analysis of CBF-AML.
The number of included studies, number of patients in the included studies, and percentage of patients with KIT mutations in the included studies are listed.
Table 3.
Meta-analysis results by ethnicity.
Table 4.
Studies assessing the prognostic relevance of KIT mutations in CBF-AML and subgroups in a systematic review.